Risk Factors Update Summary

• Mention of "gene therapies" and "AT - GAA" expands the focus to gene therapy products.
• Discussion of "manufacturing issues" and reliance on WuXi Biologics stresses supply chain risks.
• Added warrants to potential sources of capital raising, increasing flexibility for financing. This could impact liquidity.
• Added potential risks from environmental, social, and governance matters, impacting business reputation and operations.
• Addition of "and maintain" emphasizes the importance of sustaining market acceptance of Galafold®.
• Addition of "AT - GAA" in various sections underscores the significance of this product.
• Extended Senior Secured Term Loan maturity from 2026 to 2029, affecting long-term debt obligations.
• Expanded NOLs from $1.2 billion to $1.0 billion, impacting tax benefits and future tax liabilities.
• Inclusion of "products" instead of "product" highlights the need to commercialize multiple products.
• Inclusion of "Pombiliti™ + Opfolda™" in distribution agreements highlights future commercialization plans.
• Increased net proceeds from $385 million to $387 million, impacting available funds.
• Extended NOL expiration from 2029 to 2042, affecting tax planning and liabilities.
• Reference to "Pombiliti™ + Opfolda™" facing generic competition indicates potential revenue impact.
• Adjusted interest rate from 6.5% to 6.25% per annum, affecting interest payments.